IRIsabelle Rydén

Isabelle Rydén

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabelle Rydén has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Breaking barriers and shaping futures: A sequential multi-methods exploration of career pathways for nurses and allied health professionals

    by Aoife Williamson, Lena Rosenlund, Karin Piil, Sara Nordentoft, Sara Melhuish, Isabelle Rydén, Marike Donders-Kamphuis, Sharon Fernandez, Helle Sorenson von Essen, Georgia Halkett, et al.

    Background: Nurses and Allied Health Professionals (AHPs) are essential to neuro-oncology multidisciplinary teams (MDTs) in delivering holistic, person-centered care. Despite their central role, the career development landscape for neuro‑oncology nurses and AHPs remains fragmented, with limited opportunities for structured progression, advanced training, or protected time for professional growth. We aimed to identify key barriers to professional development and generate practical, actionable strategies to build capacity. Methods: We conducted qualitative focus groups with neuro-oncology nurses and AHPs to generate barriers and solutions to career development and progression, followed by a quantitative survey to rank barriers and solutions for priority and feasibility. A rapid qualitative synthesis of focus group findings informed the survey questions, which were analyzed descriptively. Based upon expert consensus, a set of practical and actionable solutions was proposed. Results: Ten nurses and AHPs took part, representing Sweden, Denmark, the United Kingdom, and the Netherlands, and included junior- and senior-level roles. Across 4 topics (variability in education opportunities, the MDT environment, practical barriers, and building the next generation), a total of 23 barriers and 32 solutions were generated in focus groups and then ranked in the survey exercise. Ten action points were generated to guide the strategy of the EANO Nurse and Allied Health Professions Committee. Conclusions: The collective insights of nurses and AHPs from different countries, at different career stages, helped shape a robust strategic action plan. Grounded in real‑world experiences and shared challenges, our results offer a practical roadmap for strengthening capacity and supporting career development.

  • Open Access

    Persistent fatigue after surgery for asymptomatic meningiomas: A population-based long-term follow-up study

    by Olivia Näslund, Isabelle Rydén, Stina Rittri, Jenny Pettersson-Segerlind, Jiri Bartek, Erik Thurin

    Background: Meningiomas are increasingly detected incidentally due to widespread neuroimaging and are sometimes managed surgically despite the absence of preoperative symptoms. Although surgery in these patients is often considered to be of low risk, long-term patient-reported outcomes such as fatigue remain insufficiently characterized. Objective: To assess the prevalence and severity of long-term fatigue in patients surgically treated for asymptomatic meningiomas. Methods: In this population-based retrospective cohort study, adult (≥18 years) patients with asymptomatic meningioma treated surgically at Karolinska University Hospital between 2007 and 2013 (n = 69) were included. Patients were assessed using the Multidimensional Fatigue Inventory (MFI-20) and compared with age- and sex-matched normative values. The proportion of patients with clinically significant fatigue was estimated using validated cut-off scores based on previous studies. Results: The median total fatigue score was 55 (IQR 45-63), corresponding to approximately 0.7 SDs above age- and sex-matched normative values. Patients reported significantly higher fatigue levels than normative values across all MFI-20 dimensions (all P < .001). Fatigue was present in 33% of patients based on total fatigue scores, while 48%-64% exceeded cut-off values in individual fatigue dimensions present in MFI-20. Descriptive differences in fatigue scores were observed across age groups and between sexes Conclusion: Patients surgically treated for asymptomatic meningiomas experience elevated multidimensional fatigue at long-term follow-up. These findings challenge assumptions of benign postoperative recovery in this patient population and highlight the importance of systematic fatigue assessment and targeted management strategies even in previously asymptomatic patients.

  • Open Access

    Contribution of cognitive function and fatigue to health-related quality of life in patients with IDH -mutant gliomas from diagnosis to long-term follow-up

    by Isabelle Rydén, Dongni Buvarp, Alice Neimantaite, Louise Carstam, Dima Harba, Lotta Weyhenmeyer, Andrew Lycett, Sigrid Malmqvist, Anneli Ozanne, Erik Elgeskog, et al.

    Background: Cognitive impairment, fatigue, and reduced health-related quality of life (HRQoL) are common in patients with IDH-mutant gliomas. However, it remains unclear which cognitive domains are most relevant for global HRQoL, how fatigue relates to these associations, and whether this differs across disease stages. This cross-sectional study examined associations between impairments in cognitive domains and global HRQoL across the disease trajectory. Methods: Objective neuropsychological test results from patients with IDH-mutant gliomas were evaluated preoperatively, at 1 year, and long-term (≥ 5 years). Results were classified into 6 cognitive domains. HRQoL was assessed using the EORTC QLQ-C30 global health score. Hierarchical regression models were applied at each time point, adjusting for age and sex. Sensitivity analyses examined the contribution of fatigue and anxiety/depression. Results: Preoperatively (n = 106 patients), impairments in cognitive domains significantly explained additional variance beyond demographic variables (ΔR² = 0.20, p < .001), with impairments in learning/memory associated with lower global HRQoL (p < .001). At 1 year (n = 106 patients), cognitive domains also explained additional variance (ΔR ² = 0.16, p < .01), with language (p < .05) and executive impairments (p < .01) as significant predictors. In the long-term cohort (n = 82 patients), cognitive domains explained additional variance (ΔR² = 0.31, p < .001), with executive impairments showing the strongest association (p < .001). Fatigue was strongly associated with global HRQoL across time points (p < .001). Anxiety/depression showed weaker associations. Conclusions: Associations between cognitive functioning and global HRQoL differ across time points, with executive impairments showing the strongest associations. Fatigue represents an important co-occurring factor. These symptoms are potentially modifiable, indicating that rehabilitation may improve patients’ HRQoL.

  • Open Access

    Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study

    by Isabelle Rydén, Francesco Latini, Åsa Alberius Munkhammar, Per Hellström, Alice Neimantaite, Andrew Lycett, Dima Harba, Louise Carstam, Malin Blomstrand, Maria Zetterling, et al.

    Background: Management of isocitrate dehydrogenase (IDH) mutated gliomas is multidisciplinary and current guidelines support early multimodal treatment. The effects of this treatment approach on cognition are less studied. We aimed to study changes in cognitive functioning the first year following treatment in these patients and explore predictors of cognitive deterioration. Methods: Patients with a first-time diagnosis of IDH mutated glioma were neuropsychologically assessed before and one year after surgery. Results were compared to published norms, and impairment defined as z <−1.645. Matched controls were assessed at corresponding times, and reliable change indices (RCIs) were calculated to account for practice effects. Logistic regression models investigated predictors for cognitive declines. Tumor locations for declined versus non-declined patients were visualized using heatmaps. Results: Of the 127 included patients, 104 underwent multi-modal treatment. Pre-operative impairments ranged from 3% to 24%, depending on the specific test. Cognitive declines according to RCI domains were largest in tests of executive functioning (24%), learning/memory (23%), and language (21%). Tests of inhibition/flexibility (32%), naming speed (29%), verbal memory (28%), object naming (28%), and verbal fluency (22%) showed the largest proportions of declines. Regression models revealed that older age and chemoradiotherapy predicted declines in specific domains as well as in individual tests (P < 0.05). Conclusions: Significant changes occurred in several cognitive domains after guideline-based treatment. Older age and chemoradiotherapy increased the risk of cognitive declines one year after surgery, but to which extent the deficits are persistent or progressing remains unknown.


  • Open Access

    Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

    by Florien W Boele, Sé M Frances, Amélie Darlix, Francois Ducray, Stéphanie Cartalat, Estelle Guerdoux, Emeline Tabouret, Michael C Burger, Isabelle Rydén, Annika Malmstrom, et al.

    Background: Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma. Methods: In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥ 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor location; treatments delivered; time since treatment; current medication) were explored with regression analyses. Results: In total, 237 patients M = 9.9 years postdiagnosis (SD = 4.2, range 5.0-25.8) took part from 33 sites across 9 countries. Clinically relevant levels of impairment were noted in >40% of patients on EORTC QLQ-C30 scales for cognitive functioning (56.1%), emotional functioning (49.8%), fatigue (45.1%), and physical functioning (40.5%). In individuals, cognitive impairment ranged from 17.7% for processing speed to 46.0% for episodic verbal memory (delayed recall). Among other clinical factors such as current use of antiseizure medication or antidepressants, age, disease progression, time since diagnosis and time since treatment, and radiotherapy treatment (ever received) was linked to HRQOL and cognitive functioning outcomes (posthoc analyses for cumulative radiotherapy dose: not significant). Conclusions: In oligodendroglioma survivors, HRQOL and cognitive impairment are prevalent even years into follow-up. Supportive care and rehabilitation should be prioritized to mitigate these challenges and improve daily functioning. Trial registration: NCT04708548


  • Inequalities in access to neuro-oncology supportive care and rehabilitation: A survey of healthcare professionals’ perspectives

    by Florien Boele, Lena Rosenlund, Sara Nordentoft, Sara Melhuish, Emma Nicklin, Isabelle Rydén, Aoife Williamson, Marike Donders-Kamphuis, Matthias Preusser, Emilie Le Rhun, et al.

    Background: Neuro-oncology patients and caregivers should have equitable access to rehabilitation, supportive-, and palliative care. To investigate existing issues and potential solutions, we surveyed neuro-oncology professionals to explore current barriers and facilitators to screening patients’ needs and referral to services. Methods: Members of the European Association of Neuro-Oncology and the European Organisation for Research and Treatment of Cancer Brain Tumor Group (EORTC-BTG) were invited to complete a 39-item online questionnaire covering the availability of services, screening, and referral practice. Responses were analyzed descriptively; associations between sociodemographic/clinical variables and screening/referral practice were explored. Results: In total, 103 participants completed the survey (67% women and 57% medical doctors). Fifteen professions from 23 countries were represented. Various rehabilitation, supportive-, and palliative care services were available yet rated “inadequate” by 21–37% of participants. Most respondents with a clinical role (n = 94) declare to screen (78%) and to refer (83%) their patients routinely for physical/cognitive/emotional issues. Survey completers (n = 103) indicated the main reasons for not screening/referring were (1) lack of suitable referral options (50%); (2) shortage of healthcare professionals (48%); and (3) long waiting lists (42%). To improve service provision, respondents suggested there is a need for education about neuro-oncology-specific issues (75%), improving the availability of services (65%) and staff (64%), developing international guidelines (64%), and strengthening the existing evidence-base for rehabilitation (60%). Conclusions: Detecting and managing neuro-oncology patients’ and caregivers’ rehabilitation, supportive,- and palliative care needs can be improved. Better international collaboration can help address healthcare disparities.


  • Open Access

    Global health status and fatigue score in isocitrate dehydrogenase-mutant diffuse glioma grades 2 and 3: A longitudinal population-based study from surgery to 12-month follow-up

    by Tomás Gómez Vecchio, Isabelle Rydén, Anneli Ozanne, Malin Blomstrand, Louise Carstam, Anja Smits, Asgeir Store Jakola

    At the group level, health-related quality of life (HRQoL) in patients with IDH-mutant diffuse glioma grades 2 and 3 seems to remain stable over time. However, clinical experience indicates that there are patients with unfavorable outcomes on key HRQoL subdomains. The aim of this longitudinal population-based study, following patients over a period of 12 months from surgery, was to describe individual-level data on global health status and fatigue score and explore possible predictors of deterioration. All patients undergoing surgery for presumed glioma grades 2 or 3 at the Sahlgrenska University Hospital during 2017–2022, were screened for the study. Patients were invited to complete the European Organization of Research and Treatment of Cancer core questionnaires and brain module at baseline, 3 and 12 months postoperatively. Data is reported with respect to minimal clinical important difference (MCID). We included 51 patients with IDH-mutant diffuse glioma grades 2 or 3. There was no difference in group-level data of either global health status or fatigue score from baseline to the 12-month follow-up (P-value > .05). Unfavorable individual changes (beyond MCID) in global health status and fatigue score were observed in 12 and in 17 patients, respectively (23.5% and 33.3%). A lower proportion of proton radiotherapy was found in patients with unfavorable changes in fatigue (10/15, 66.7%) compared to all other patients undergoing radiotherapy (22/23, 95.7%, P-value .03). Deterioration beyond MCID was seen in approximately one-third of patients. Changes in global health status could not be predicted, but changes in fatigue may be influenced by tumor-targeted and symptomatic treatment.


  • Open Access

    Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH- mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden

    by Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hillevi Rylander, Cecilie Kiserud, Tonje Haug Nordenmark, Taran Paulsen Hellebust, Morten Egeberg Evensen, Magnus Gustavsson, Christina Ramberg, Mette Sprauten, et al.

    Introduction: The use of proton therapy increases globally despite a lack of randomised controlled trials demonstrating its efficacy and safety. Proton therapy enables sparing of non-neoplastic tissue from radiation. This is principally beneficial and holds promise of reduced long-term side effects. However, the sparing of seemingly non-cancerous tissue is not necessarily positive for isocitrate dehydrogenase ( IDH )-mutated diffuse gliomas grade 2–3, which have a diffuse growth pattern. With their relatively good prognosis, yet incurable nature, therapy needs to be delicately balanced to achieve a maximal survival benefit combined with an optimised quality of life. Methods and analysis: PRO-GLIO (PROton versus photon therapy in IDH -mutated diffuse grade 2 and 3 GLIOmas) is an open-label, multicentre, randomised phase III non-inferiority study. 224 patients aged 18–65 years with IDH -mutated diffuse gliomas grade 2–3 from Norway and Sweden will be randomised 1:1 to radiotherapy delivered with protons (experimental arm) or photons (standard arm). First intervention-free survival at 2 years is the primary endpoint. Key secondary endpoints are fatigue and cognitive impairment, both at 2 years. Additional secondary outcomes include several survival measures, health-related quality of life parameters and health economy endpoints. Ethics and dissemination: To implement proton therapy as part of standard of care for patients with IDH -mutated diffuse gliomas grade 2–3, it should be deemed safe. With its randomised controlled design testing proton versus photon therapy, PRO-GLIO will provide important information for this patient population concerning safety, cognition, fatigue and other quality of life parameters. As proton therapy is considerably more costly than its photon counterpart, cost-effectiveness will also be evaluated. PRO-GLIO is approved by ethical committees in Norway (Regional Committee for Medical & Health Research Ethics) and Sweden (The Swedish Ethical Review Authority) and patient inclusion has commenced. Trial results will be published in international peer-reviewed journals, relevant conferences, national and international meetings and expert forums. Trial registration number: ClinicalTrials.gov Registry ( NCT05190172 ).


  • Open Access

    Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period

    by Caroline Svenjeby, Louise Carstam, Katja Werlenius, Thomas Olsson Bontell, Isabelle Rydén, Julia Jacobsson, Anna Dénes, Asgeir S. Jakola, Alba Corell

    Background: Isocitrate dehydrogenase (IDH) mutated diffuse lower-grade gliomas (dLGG) are infiltrating brain tumors and increasing evidence is in favor of early multimodal treatment. In a Scandinavian population-based setting, we wanted to study treatment patterns over the last 15 years, focusing on the short-term postoperative course to better understand the potential negative consequences of treatment. Methods: Patients ≥ 18 years with primary IDH-mutated dLGG grade 2 and 3, operated between January 2007–June 2021 were identified. Patients were divided into subgroups (2007–2011, 2012–2016, and 2017–2021) and comparisons regarding tumor- and disease characteristics, treatment, and postoperative outcome were performed. Results: We identified 202 patients (n = 61, 2007–2011; n = 72, 2012–2016; n = 69, 2017–2021), where of 193 underwent resection without change in proportion of resections over time. More patients underwent complete resections in recent times (6.1%; 15.7%; 26.1%, respectively; p = 0.016). Forty-two patients had any neurological deficit postoperatively (14.8%; 23.6%; 23.2%; p = 0.379), mostly minor and transient. Differences in oncological therapy were seen between the investigated subgroups. Early radiotherapy alone (32.8%; 7%; 2.9%; p < 0.001), concomitant chemoradiotherapy (23%; 37.5%; 17.4%; p = 0.022), sequential chemoradiotherapy (0%; 18%; 49.3%; p < 0.001), and no adjuvant treatment (42.6%; 23.6%; 18.8%; p = 0.009) shifted during the studied period. Increasingly more patients received proton radiotherapy compared to photon radiotherapy during the later time periods (p < 0.001). Conclusion: Complete resections were performed more often in later time periods without an apparent increase in surgical morbidity. Early adjuvant oncological treatment shifted towards providing chemotherapy and combined chemoradiotherapy more often in later time periods. Protons replaced photons as the radiation modality of choice.


  • Open Access

    Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study

    by Isabelle Rydén, Erik Thurin, Louise Carstam, Anja Smits, Sasha Gulati, Roger Henriksson, Øyvind Salvesen, Asgeir Store Jakola